Adenoviruses as vectors for HIV vaccines

AIDS Reviews

Volumn 5, Issue 3, 2003, Pages 178-185

  Gómez Román, Víctor Raúl ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenovirus; AIDS vaccine; Cellular immunity; HIV; Humoral immunity; Mucosal immunity; Non human primates; SIV

Indexed keywords

ADENOVIRUS TYPE 4 VACCINE; ADENOVIRUS TYPE 7 VACCINE; ADENOVIRUS VECTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; POLIOMYELITIS VACCINE; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; ADENOVIRUS; CELLULAR IMMUNITY; CHIMERA; CLINICAL TRIAL; DEFECTIVE VIRUS; DRUG DESIGN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOCOMPETENCE; IMMUNOGENICITY; MUCOSAL IMMUNITY; NONHUMAN; PRIMATE; REVIEW; RHESUS MONKEY; SIMIAN VIRUS; VIROGENESIS; VIRUS GENOME; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; ANTIBODY FORMATION; GENETIC VECTORS; HIV INFECTIONS; HUMANS; IMMUNITY, CELLULAR; VIRUS REPLICATION;

EID: 0242351940     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (74)

1. Rowe W, Huebner A, Gilmore L, Parrot R, Ward T. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953;84:570-3.
2. Hilleman M, Werner J. Recovery of a new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 1954;85:183-8.
3. De Jong J, Wermenbol A, Verweij-Uijterwaal M, et al. Adenoviruses from human immunodeficiency virus-infected individuals, including two-strains that represent new candidate serotypes Ad50 and Ad51 of species B1 and D, respectively. J Clin Microbiol 1999;37:3940-5.
4. Wadell G. Molecular epidemiology of adenoviruses. Curr Top Microbiol Immunol 1984;110:191-220.
5. Vermut M. The architecture of adenoviruses. In: Ginsberg HS (ed). The Adenoviruses. New York: Plenum Press 1984:5-34.
6. Howitt J, Anderson C, Freimuth P. Adenovirus interaction with its cellular receptor CAR. Curr Top Microbiol Immunol 2003;272:331-64.
7. Wickham T, Mathias P, Cheresh D, Nemerow G. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993;73:309-19.
8. Croyle M, Cheng X, Wilson J. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther 2001;8:1281-90.
9. Natuk R, Davis A, Chanda P, et al. Adenovirus vectored vaccines. Dev Biol Stand 1994;82:71-7.
10. Lubeck M, Natuk R, Myagkikh M, et al. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nature Med 1997;3:651-8.
11. Fitzgerald J, Gao G, Reyes-Sandoval A, et al. A Simian replication-defective adenoviral recombinant vaccine to HIV-1 Gag. J Immunol 2003;170:1416-22.
12. Klessig D, Grodzicker T. Mutations that allow human Ad2 and Ad5 to express late genes in monkey cells map in the viral gene encoding the 72K DNA binding protein. Cell 1979;17:957-66.
13. Cheng S, Lee S, Ronchetti-Blume M, et al. Co-expression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J Virol 1992;66:6721-7.
14. Patterson L, Prince G, Richardson E, Alvord W, Kalyan N, Robert-Guroff M. Insertion of HIV-1 genes into Ad4Δ E3 vector abrogates increased pathogenesis in cotton rats due to E3 deletion. Virology 2002;292:107-13.
15. Natuk R, Chanda P, Lubeck M, et al. Adenovirus-HIV envelope recombinant vaccines elicit high-titered HIV-neutralizing antibodies in the dog model. Proc Natl Acad Sci USA 1992;89:7777-81.
16. Prevec L, Christine B, Laurie K, Bailey M, Graham F, Rosenthal K. Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J Acquir Immune Defic Syndr 1991;4:568-76.
17. Natuk R, Lubeck M, Chanda P, et al. Immunogenicity of recombinant human adenovirus-HIV vaccines in chimpanzees. AIDS Res Hum Retroviruses 1993;9:395-404.
18. Lubeck M, Natuk R, Chengalvala M, et al. Immunogenicity of recombinant adenovirus-HIV vaccines in chimpanzees following intranasal administration. AIDS Res Hum Retroviruses 1994;10:1443-9.
19. Robert-Guroff M, Kaur H, Patterson L, et al. Vaccine protection against a heterologous, non-syncytium-inducing, primary HIV. J Virol 1998;72:10275-80.
20. Zolla-Pazner S, Lubeck M, Xu S, et al. Induction of neutralizing antibodies in chimpanzees to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime/boost vaccine regimen in chimpanzees. J Virol 1998;72:1052-9.
21. Flanagan B, Pringle C, Leppard K. A recombinant human adenovirus expressing the simian immunodeficiency virus Gag antigen can induce long-lived immune responses in mice. J Gen Virol 1997;78:991-7.
22. Buge S, Richardson E, Alipanah S, et al. An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J Virol 1997;71:8531-41.
23. Buge S, Murty L, Arora K, et al. Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming/gp120 boosting regimen and challenged vaginally with SIV-mac251. J Virol 1999;73:7430-40.
24. Zhao J, Lou Y, Pinczewski A, et al. Boosting of SIV-specific cellular immune responses in rhesus macaques by repeated administration of Ad5hr-SIV env/rev and SIV gag recombinants. Vaccine 2003;21:4022-35.
25. Zhao J, Pinczewski J, Gómez-Román V, et al. Improved protection of rhesus macaques against intrarectal SIVmac251 challenge by a replication competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen. J Virol 2003;77:8354-65.
26. Malkevitch N, Patterson L, Aldrich K, Richardson E, Alvord W, Robert-Guroff M. A replication competent Ad5hr-SIV recombinant priming/subunit protein boosting vaccine regimen induces broad, persistent SIV-specific cellular immunity to dominant and subdominant epitopes in mamu-A*01 rhesus macaques. J Immunol 2003;170:4281-9.
27. Patterson L, Malkevitch N, Pinczewski J, et al. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIVgp120. J Virol 2003;77:8607-20.
28. Bruce C, Akrigg A, Sharpe S, Hanke T, Wilkinson G, Cranage M. Replication-deficient recombinant adenoviruses expressing the HIV Env antigen can induce both humoral and CTL immune responses in mice. J Gen Virol 1999;80:2621-8.
29. Yoshida T, Okuda K, Xin K-Q, et al. Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin Exp Immunol 2001;124:445-52.
30. Casimiro D, Chen L, Fu T-M, et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a HIV type 1 gag gene. J Virol 2003;77:6305-13.
31. Vinner L, Wee EG-T, Patel S, et al. Immunogenicity in Mamu-A*01 rhesus macaques of a CCR5-tropic HIV type 1 envelope from the primary isolate (Bx08) after synthetic DNA prime and recombinant adenovirus 5 boost. J Gen Virol 2003;84:203-13.
32. Chenciner N, Randrianarison-Jewtoukoff V, Delpeyroux F, et al. Enhancement of humoral immunity to SIVenv following simultaneous inoculation of mice by three recombinant adenoviruses encoding SIVenv/poliovirus chimeras, tat and rev. AIDS Res Hum Retroviruses 1997;13:801-6.
33. Shiver JW, Fu T-M, Chen L, et al. Replication-incompetent adenovirus vaccine vector elicits effective anti-HIV immunity. Nature 2002;415:331-5.
34. Fitzgerald J, Gao G-P, Reyes-Sandoval A, et al. A simian replication-defective adenovirus recombinant vaccine to HIV-1 gag. J Immunol 2003;170:1416-22.
35. Shenk T. Adenoviridae: The viruses and their replication. In: Knipe DM, Howley PM, Griffin DE, et al. (eds). Fields Virology. 4th ed. Philadelphia: Lippincott, Williams & Wilkins: 2001:2265-300.
36. Gerhard-Burgert H, Blusch J. Immunomodulatory functions encoded by the E3 transcription unit of adenoviruses. Virus Genes 2000;21:13-25.
37. Patterson L, Peng B, Nan X, Robert-Guroff M. Live adenovirus recombinants as vaccine vectors. In: Levine M, Kaper J, Rappuoli, R, Liu M, Good M (eds). New Generation Vaccines. 3rd ed. New York: Marcel Dekker, Inc. 2003 (in press).
38. Graham F, Smiley J, Russell W, Nairn F. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977;36:59-74.
39. Lewis A, Krause P, Peden K. A defined-risks approach to the regulatory assessment of the use of neoplastic cells as substrates for viral vaccine manufacture. Dev Biol Basel, Karger, 2001;106:513-35.
40. Shiver J, Casimiro D, Liang X, et al. Replication-defective adenovirus vector vaccines attenuate SIVmac239 and SHIV89.6P challenge infections: Effects of challenge virus, MHC class I expression and multiple vaccine antigen expression. 10th CROI. Boston 2003.
41. Feinberg M, Moore J. AIDS vaccine models: Challenging challenge viruses. Nature Med 2002;8:207-10.
42. Wei X, Decker J, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature 2003;422:307-12.
43. Barouch D, Kunstman J, Kuroda M, et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T-lymphocytes. Nature 2002;415:335-9.
44. O'Connor D, Allen T, Watkins D. Cytotoxic T-lymphocytes escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol 2002;21:659-64.
45. Yang O, Sarkis P, Ali A, et al. Determinant of HIV-1 mutational escape from cytotoxic T-lymphocytes. J Exp Med 2003;197:1365-75.
46. Amara R, Villinger F, Altman J, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001;292:69-74.
47. Rose N, Marx P, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001;106:539-49.
48. Pal R, Venzon D, Letvin N, et al. ALVAC-SIV-gag-pol-env based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIV-mac-induced immunodeficiency. J Virol 2002;76:292-302.
49. Hel Z, Nasca J, Tryniszewska E, et al. Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and post-challenge CD4+ and CD8+ T-cell responses. J Immunol 2002;169:4778-87.
50. Horton H, Vogel T, Carter D, et al. Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002;76:7187-202.
51. Ourmanov I, Brown C, Moss B, et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000;74:2740-51.
52. Davis N, Caley I, Brown K, et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J Virol 2000;74:371-8.
53. Murphy C, Lucas W, Means R, et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000;74:7745-54.
54. Evans D, Chen L-M, Gillis J, et al. Mucosal priming of simian immunodeficiency virus-specific cytotoxic T-lymphocyte responses in rhesus macaques by the Salmonella type III secretion antigen delivery system. J Virol 2003;77:2400-9.
55. Dai Y, Schwarz E, Gu D, Zhang W-W, Sarvetnick N, Verma I. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995;92:1402-5.
56. Xiang Z, Ertl H. Induction of mucosal immunity with a replication-defective adenoviral recombinant. Vaccine 1999;17:2003-8.
57. IAVI Report. Update on Merck's AIDS Vaccine Program. February/April, 2003.
58. Yang Z, Wyatt L, Kong W, Moodie Z, Moss B, Nabel G. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003;77:799-803.
59. Gaydos C, Gaydos J. Adenovirus vaccines in the U.S. military. Mil Med 1995;160:300-4.
60. Ryan M, Gray G, Smith B, McKeehan J, Hawksworth A, Malasig M. Large epidemic of respiratory illness due to adenovirus types 7 and 3 in healthy young adults. Clin Infect Dis 2001;34:577-82.
61. Centers for Disease Control and Prevention. Two fatal cases of adenovirus-related illness in previously healthy young adults - Illinois, 2000. MMWR Morb Mortal Wkly Rep 2001;50:26-8.
62. Knowles M, Hohneker K, Zhou Z, et al. A controlled study of adenovirus-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. N Engl J Med 1995;333:823-31.
63. Zabner J, Ramsey B, Meeker D, et al. Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis. J Clin Invest 1996;97:1504-11.
64. Smith T, Buescher E, Top F, Altemeier W, McCown J. Experimental respiratory infection with type-4 adenovirus vaccine in volunteers: Clinical and immunological responses. J Infec Dis 1970;122:239-48.
65. Gutekunst R, White R, Edmondson W, Chanock R. Immunization with live type-4 adenovirus: Determination of infectious virus dose and protective effect of enteric infection. Am J Epidemiol 1967;86:341-9.
66. Stanley E, Jackson G. Spread of enteric live adenovirus type-4 vaccine in married couples. J Infec Dis 1969;199:51-9.
67. Mueller R, Muldoon R, Jackson G. Communicability of enteric live adenovirus type-4 vaccine in families. J Infect Dis 1969;199:60-6.
68. Green M, Wold W, Brackman K, et al. Human adenovirus transforming genes: Group relationship, integration, expression in transformed cells, and analysis of human cancers and tonsils. In: Essex M, Todaro G, Zur Hausen H (eds). Viruses in Naturally Occurring Cancers: Cold Spring Harbor Conferences on Cell Proliferation. Vol 7. New York: Cold Spring Harbor Press, Cold Spring Harbor 1980:373-97.
69. Frisch S, Mymryk J. Adenovirus-5 E1A: Paradox and paradigm. Nature Rev Mol Cel Biol 2002;3:441-52.
70. Herremans T, Reimerink J, Buisman A, Kimman T, Koopmans M. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus. J Immunol 1999;162:5011-8.
71. Einfeld D, Roelvink P. Advances towards targetable adenovirus vectors for gene therapy. Curr Opin Mol Ther 2002; 4:444-51.
72. Henning P, Magnusson M, Gunneriusson E, et al. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. Hum Gene Ther 2002; 13:1427-39.
73. Einfeld D, Schroeder R, Roelvink P, et al. Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions. J Virol 2001;75:11284-91.
74. Kojaoghlanian T, Flomenberg P, Horwitz M. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol 2003;13:155-71.